|
Spain-VT-VT Directorios de empresas
|
Noticias de la compañía :
- Nutrients and amyloid β status in the brain: A narrative review
In contrast, higher HDL levels and a higher concentration of polyunsaturated triglycerides (PUTG) was associated to increased Aβ42 blood levels (Bernath et al , 2020) (Table 2)
- UC study: Alzheimer’s drug may work by boosting brain protein levels . . .
A study led by University of Cincinnati researchers found that new monoclonal antibody drugs for Alzheimer’s may slow cognitive impairment through boosting levels of the protein Aβ42 in the brain
- High-Intensity Physical Activity Modulates Diet Effects on . . .
Importantly, diet effects on this AD biomarker differed for normal and MCI groups For normals, CSF Aβ42 levels were reduced with the LOW diet but increased with the HIGH diet In MCI, the reverse pattern was observed
- Alzheimers decline may be slowed by protein boost - Newsweek
"We discovered that what keeps people with amyloid plaques cognitively normal is the extent to which they are able to produce enough Aβ42, an important protein for brain health, to keep it
- Alzheimers: Boosting brain protein may slow cognitive decline
After analyzing the study data, researchers discovered that higher levels of Aβ42 after monoclonal antibody treatment were independently associated with slower cognitive impairment and
- Boosting brain protein levels may slow decline from Alzheimer’s
They found that higher levels of Aβ42 after treatment were independently associated with slower cognitive impairment and clinical decline “All stories have two sides — even the one we have told ourselves about how anti-amyloid treatments work: by lowering amyloid,” Espay said
- New Drugs Fight Alzheimer’s by Increasing Amyloid Beta Reducing . . .
How do the new drugs Leqembi and Kisunla fight Alzheimer's? Surprisingly, increases in amyloid-beta protein levels can explain the slowing of Alzheimer's at least as well as the reduction in amyloid plaques
- Boosting Brain Protein May Slow Alzheimer’s Decline
Higher levels of amyloid-beta are associated with slower cognitive deterioration Researchers analyzed the study data and found that slower cognitive impairment and clinical decline were independently linked to greater levels of Aβ42 following monoclonal antibody treatment
- Rethinking Alzheimers: Increasing Amyloid-β42 Slows Disease . . .
These results highlight the need to explore therapies that directly raise Aβ42 levels without targeting amyloid plaques, providing a fresh perspective on Alzheimer’s treatment
- Boosting brain protein levels may slow decline from Alzheimer’s
A study found that new monoclonal antibody drugs for Alzheimer's may slow cognitive impairment through boosting levels of a specific protein in the brain
|
|